Loading...

Purified anti-mouse CD80 Antibody Purified anti-mouse CD80 Antibody

Pricing & Availability
Clone
16-10A1 (See other available formats)
Regulatory Status
RUO
Other Names
B7-1, B7, Ly-53
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
16-10A1_Purified_CD80_Antibody_FC_090414.jpg
LPS-stimulated (3 days) BALB/c splenocytes stained with purified CD80 (clone 16-10A1, filled histogram) or Armenian hamster IgG isotype control (open histogram), followed by goat anti-Armenian hamster IgG PE.
  • 16-10A1_Purified_CD80_Antibody_FC_090414.jpg
    LPS-stimulated (3 days) BALB/c splenocytes stained with purified CD80 (clone 16-10A1, filled histogram) or Armenian hamster IgG isotype control (open histogram), followed by goat anti-Armenian hamster IgG PE.
Compare all formats
Cat # Size Price Quantity Check Availability Save
104702 500 µg NOK1139
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD80 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD80 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD80 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD80 appears to be expressed later in the immune response than CD86. CD80 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Reported Reactivity
Dog
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
CHO cell line transfected with mouse B7 (CD80)
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
Block, IHC-F, IP - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation2, in vitro and in vivo blocking of CTLA-4 Ig to CD80 by blocking costimulation of T cells by activated B cells2-4, and immunohistochemical staining of acetone-fixed frozen sections1,4. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104747-104752).

Application References
  1. Harlan DM, et al. 1994. P. Natl. Acad. Sci. USA 91:3137. (IHC)
  2. Razi-Wolf Z, et al. 1992. P. Natl. Acad. Sci. USA 89:4210. (Block, IP)
  3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
  4. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
  5. Ma XT, et al. 2006. Cancer Res. 66:1169.
  6. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC)
  7. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  8. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
  9. Misra RS, et al. 2010. J. Exp Med. 207:1775. PubMed
  10. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  11. Philipsen L, et al. 2013. Mol Cell Proteomics. 12:2551. PubMed
Product Citations
  1. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  2. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  3. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  4. Cai S, et al. 2020. Sci Rep. 10:14249. PubMed
  5. Malinczak CA, et al. 2021. J Immunol. 206:1315. PubMed
  6. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  7. Wan Mohd Zawawi WFA, et al. 2021. Sci Rep. 11:10278. PubMed
  8. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  9. Kouwenberg M, et al. 2020. PLoS One. 15:e0230835. PubMed
  10. Niss Arfelt K, et al. 2017. Blood. 129:866. PubMed
  11. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  12. Chen L, et al. 2020. Front Immunol. 11:584458. PubMed
  13. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
  14. Forsyth KS, et al. 2020. PLoS Pathog. 16:e1008685. PubMed
  15. Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed
  16. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
  17. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  18. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
  19. Hammer A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01922. PubMed
  20. Song K, et al. 2017. Oncotarget. 8:38554. PubMed
  21. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  22. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  23. Wu J, et al. 2017. Am J Pathol. 10.1016/j.ajpath.2016.12.021. PubMed
  24. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
  25. Lou F, et al. 2020. Immunity. 53(1):204-216.e10. PubMed
  26. Andrews AR, et al. 2019. Cancer Cell Int. 0.955555556. PubMed
  27. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
  28. Khameneh HJ, et al. 2017. J Immunol. 198:196. PubMed
  29. Klinger M, et al. 2007. Am J Physiol Regul Integr Comp Physiol. 293:R677. PubMed
  30. Prabakaran T, et al. 2021. EBioMedicine. 66:103314. PubMed
  31. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  32. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  33. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  34. Cai S, et al. 2020. Sci Rep. 10:14249. PubMed
  35. Malinczak CA, et al. 2021. J Immunol. 206:1315. PubMed
  36. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  37. Wan Mohd Zawawi WFA, et al. 2021. Sci Rep. 11:10278. PubMed
  38. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  39. Kouwenberg M, et al. 2020. PLoS One. 15:e0230835. PubMed
  40. Niss Arfelt K, et al. 2017. Blood. 129:866. PubMed
  41. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  42. Chen L, et al. 2020. Front Immunol. 11:584458. PubMed
  43. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
  44. Forsyth KS, et al. 2020. PLoS Pathog. 16:e1008685. PubMed
  45. Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed
  46. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
  47. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  48. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
  49. Hammer A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01922. PubMed
  50. Song K, et al. 2017. Oncotarget. 8:38554. PubMed
  51. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  52. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  53. Wu J, et al. 2017. Am J Pathol. 10.1016/j.ajpath.2016.12.021. PubMed
  54. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
  55. Lou F, et al. 2020. Immunity. 53(1):204-216.e10. PubMed
  56. Andrews AR, et al. 2019. Cancer Cell Int. 0.955555556. PubMed
  57. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
  58. Khameneh HJ, et al. 2017. J Immunol. 198:196. PubMed
  59. Klinger M, et al. 2007. Am J Physiol Regul Integr Comp Physiol. 293:R677. PubMed
  60. Prabakaran T, et al. 2021. EBioMedicine. 66:103314. PubMed
RRID
AB_313123 (BioLegend Cat. No. 104702)

Antigen Details

Structure
Ig superfamily, 60 kD
Distribution

Macrophages, activated B cells and T cells, dendritic cells

Function
T cell costimulation
Ligand/Receptor
CD28 (stimulatory), CD152(CTLA4) (inhibitory)
Cell Type
B cells, Dendritic cells, Macrophages, T cells, Tregs
Biology Area
Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Linsley PS, et al. 1991. J. Exp. Med. 174:561.
3. Salomon B, et al. 2001. Annu. Rev. Immunol. 19:225.

Gene ID
12519 View all products for this Gene ID
UniProt
View information about CD80 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 4    Revision Date: 08.11.2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
16-10A1 (See other available formats)
Regulatory Status
RUO
Other Names
B7-1, B7, Ly-53
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
16-10A1_Purified_CD80_Antibody_FC_090414.jpg
LPS-stimulated (3 days) BALB/c splenocytes stained with purified CD80 (clone 16-10A1, filled histogram) or Armenian hamster IgG isotype control (open histogram), followed by goat anti-Armenian hamster IgG PE.
  • 16-10A1_Purified_CD80_Antibody_FC_090414.jpg
    LPS-stimulated (3 days) BALB/c splenocytes stained with purified CD80 (clone 16-10A1, filled histogram) or Armenian hamster IgG isotype control (open histogram), followed by goat anti-Armenian hamster IgG PE.
Compare all formats
Cat # Size Price Quantity Check Availability Save
104702 500 µg NOK1139
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD80 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD80 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD80 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD80 appears to be expressed later in the immune response than CD86. CD80 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Reported Reactivity
Dog
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
CHO cell line transfected with mouse B7 (CD80)
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
Block, IHC-F, IP - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation2, in vitro and in vivo blocking of CTLA-4 Ig to CD80 by blocking costimulation of T cells by activated B cells2-4, and immunohistochemical staining of acetone-fixed frozen sections1,4. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104747-104752).

Application References
  1. Harlan DM, et al. 1994. P. Natl. Acad. Sci. USA 91:3137. (IHC)
  2. Razi-Wolf Z, et al. 1992. P. Natl. Acad. Sci. USA 89:4210. (Block, IP)
  3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
  4. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
  5. Ma XT, et al. 2006. Cancer Res. 66:1169.
  6. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC)
  7. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  8. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
  9. Misra RS, et al. 2010. J. Exp Med. 207:1775. PubMed
  10. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  11. Philipsen L, et al. 2013. Mol Cell Proteomics. 12:2551. PubMed
Product Citations
  1. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  2. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  3. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  4. Cai S, et al. 2020. Sci Rep. 10:14249. PubMed
  5. Malinczak CA, et al. 2021. J Immunol. 206:1315. PubMed
  6. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  7. Wan Mohd Zawawi WFA, et al. 2021. Sci Rep. 11:10278. PubMed
  8. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  9. Kouwenberg M, et al. 2020. PLoS One. 15:e0230835. PubMed
  10. Niss Arfelt K, et al. 2017. Blood. 129:866. PubMed
  11. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  12. Chen L, et al. 2020. Front Immunol. 11:584458. PubMed
  13. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
  14. Forsyth KS, et al. 2020. PLoS Pathog. 16:e1008685. PubMed
  15. Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed
  16. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
  17. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  18. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
  19. Hammer A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01922. PubMed
  20. Song K, et al. 2017. Oncotarget. 8:38554. PubMed
  21. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  22. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  23. Wu J, et al. 2017. Am J Pathol. 10.1016/j.ajpath.2016.12.021. PubMed
  24. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
  25. Lou F, et al. 2020. Immunity. 53(1):204-216.e10. PubMed
  26. Andrews AR, et al. 2019. Cancer Cell Int. 0.955555556. PubMed
  27. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
  28. Khameneh HJ, et al. 2017. J Immunol. 198:196. PubMed
  29. Klinger M, et al. 2007. Am J Physiol Regul Integr Comp Physiol. 293:R677. PubMed
  30. Prabakaran T, et al. 2021. EBioMedicine. 66:103314. PubMed
  31. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  32. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  33. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  34. Cai S, et al. 2020. Sci Rep. 10:14249. PubMed
  35. Malinczak CA, et al. 2021. J Immunol. 206:1315. PubMed
  36. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  37. Wan Mohd Zawawi WFA, et al. 2021. Sci Rep. 11:10278. PubMed
  38. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  39. Kouwenberg M, et al. 2020. PLoS One. 15:e0230835. PubMed
  40. Niss Arfelt K, et al. 2017. Blood. 129:866. PubMed
  41. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  42. Chen L, et al. 2020. Front Immunol. 11:584458. PubMed
  43. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
  44. Forsyth KS, et al. 2020. PLoS Pathog. 16:e1008685. PubMed
  45. Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed
  46. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
  47. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  48. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
  49. Hammer A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01922. PubMed
  50. Song K, et al. 2017. Oncotarget. 8:38554. PubMed
  51. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  52. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  53. Wu J, et al. 2017. Am J Pathol. 10.1016/j.ajpath.2016.12.021. PubMed
  54. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
  55. Lou F, et al. 2020. Immunity. 53(1):204-216.e10. PubMed
  56. Andrews AR, et al. 2019. Cancer Cell Int. 0.955555556. PubMed
  57. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
  58. Khameneh HJ, et al. 2017. J Immunol. 198:196. PubMed
  59. Klinger M, et al. 2007. Am J Physiol Regul Integr Comp Physiol. 293:R677. PubMed
  60. Prabakaran T, et al. 2021. EBioMedicine. 66:103314. PubMed
RRID
AB_313123 (BioLegend Cat. No. 104702)

Antigen Details

Structure
Ig superfamily, 60 kD
Distribution

Macrophages, activated B cells and T cells, dendritic cells

Function
T cell costimulation
Ligand/Receptor
CD28 (stimulatory), CD152(CTLA4) (inhibitory)
Cell Type
B cells, Dendritic cells, Macrophages, T cells, Tregs
Biology Area
Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Linsley PS, et al. 1991. J. Exp. Med. 174:561.
3. Salomon B, et al. 2001. Annu. Rev. Immunol. 19:225.

Gene ID
12519 View all products for this Gene ID
UniProt
View information about CD80 on UniProt.org
Go To Top Version: 4    Revision Date: 08.11.2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account